Anti-TNF Therapy in Crohn’s Disease
AbstractCrohn’s disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is increasing including younger or childhood-onset of disease. The natural history of Crohn’s disease is characterized by a remitting and relapsing course that progresses to complications and surgery in most patients. The goals of treatment are to achieve clinical and endoscopic remission, to avoid disease progression and minimise surgical resections. Medical treatment usually features antibiotics, corticosteroids, immunomodulators (thiopurines, methotrexate). Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn’s disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. There are significant considerations that need to be borne in mind, when treating patients including immunogenicity, safety profile and duration of treatment. View Full-Text
Share & Cite This Article
Adegbola, S.O.; Sahnan, K.; Warusavitarne, J.; Hart, A.; Tozer, P. Anti-TNF Therapy in Crohn’s Disease. Int. J. Mol. Sci. 2018, 19, 2244.
Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn’s Disease. International Journal of Molecular Sciences. 2018; 19(8):2244.Chicago/Turabian Style
Adegbola, Samuel O.; Sahnan, Kapil; Warusavitarne, Janindra; Hart, Ailsa; Tozer, Philip. 2018. "Anti-TNF Therapy in Crohn’s Disease." Int. J. Mol. Sci. 19, no. 8: 2244.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.